AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11712772
Drug: Web-based software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based software for site training, study documentation, subject recruitment, randomization, medication dispensing, and management procedures
Trial: 7999596
Drug: Etretinate treatment
RxNorm normalized name: etretinate
DrugBank: Etretinate (DB00926)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etretinate treatment
Trial: 2626514
Drug: Fluphenazine (mixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluphenazine (mixed D1/D2 dopamine antagonist)
Trial: 776193
Drug: Diazepam 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 0.3 mg/kg i.v. with food intake at 3 hours post-injection
Trial: 776193
Drug: Diazepam 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 0.3 mg/kg i.v. with food intake at 7 hours post-injection
Trial: 776193
Drug: Diazepam 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 0.15 mg/kg i.v. with rapid injection
Trial: 6785095
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) 40 microgram/kg via 30 min i.v. infusion
Trial: 26974423
Drug: FAST treatment
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAST treatment (20 mL/kg of crystalloid over 10 min)
Trial: 26974423
Drug: SLOW treatment
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLOW treatment (20 mL/kg of crystalloid over 30 min)
Trial: 26974423
Drug: FAST treatment
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAST treatment
Trial: 26974423
Drug: SLOW treatment
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLOW treatment
Trial: 26974423
Drug: Both FAST
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both FAST and SLOW treatments
Trial: 1490141
Drug: Vitamin B1
RxNorm normalized name: Vitamin B1
DrugBank: Monophosphothiamine (DB16023)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B1 (100 mg/day)
Trial: 25363189
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (500 mg/day)
Trial: 22267420
Drug: Melatonin 5
RxNorm normalized name: melatonin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 5 mg daily before bedtime for 30 days
Trial: 10453964
Drug: 300-mg abacavir
RxNorm normalized name: abacavir 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300-mg abacavir hemisulfate tablet (oral)
Trial: 10453964
Drug: 300-mg abacavir
RxNorm normalized name: abacavir 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300-mg abacavir hemisulfate tablet with food
Trial: 10453964
Drug: abacavir (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: abacavir (various formulations)
Trial: 31190735
Drug: Anifrolumab (fully
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anifrolumab (fully human monoclonal antibody targeting IFNAR1)
Trial: 25483366
Drug: Calcifediol (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcifediol (140 μg weekly)
Trial: 25483366
Drug: Cholecalciferol (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol (140 μg weekly)
Trial: 8287583
Drug: Interferon alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha 2b (IFN) therapy for 24 weeks
Trial: 2250886
Drug: Control eye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control eye (no treatment)
Trial: 28141897
Drug: Everolimus (EVR)
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus (EVR) with low-dose tacrolimus (LTac) and prednisone
Trial: 25721183
Drug: Sertraline (SRT,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (SRT, n = 133)
Trial: 25721183
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy (CBT, n = 139)
Trial: 25721183
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both (COMB, n = 140)
Trial: 25721183
Drug: Pill Placebo
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill Placebo (PBO, n = 76)
Trial: 23937345
Drug: D-cycloserine (DCS)
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D-cycloserine (DCS) augmentation of cognitive behavioral therapy (CBT)
Trial: 23937345
Drug: Placebo augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo augmentation of cognitive behavioral therapy (CBT)
Trial: 21521468
Drug: Nafamostat mesilate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafamostat mesilate (NM) 0.02 mg/kg
Trial: 14536040
Drug: Prototype Mk
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prototype Mk IV implant (test)
Trial: 14536040
Drug: Brånemark implant
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brånemark implant (control)
Trial: 29610765
Drug: Both test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both test and control implants
Trial: 9002829
Drug: Test implants
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test implants
Trial: 10936478
Drug: Third-generation thrombolytic
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third-generation thrombolytic agents (monteplase, tenecteplase, reteplase, lanoteplase, pamiteplase, staphylokinase)
Trial: 10936478
Drug: Second-generation agent
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation agent (alteplase)
Trial: 10936478
Drug: Third-generation thrombolytic
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third-generation thrombolytic agents
Trial: 6837243
Drug: Lidocaine 2
RxNorm normalized name: lidocaine 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2 mg/kg body weight
Trial: 30014662
Drug: Medication plus
RxNorm normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication plus rehabilitation training plus acupuncture (observation 2 group)
Trial: 30014662
Drug: Medication plus
RxNorm normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication plus rehabilitation training (observation 1 group)
Trial: 30014662
Drug: Medication alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication alone (control group)
Trial: 25689448
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate (ESL) 1,600 mg
Trial: 25689448
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate (ESL) 1,200 mg
Trial: 22029225
Drug: Esomeprazole formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole formulation 1
Trial: 22029225
Drug: Esomeprazole formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole formulation 2
Trial: 14736130
Drug: Zaleplon (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zaleplon (10 mg)
Trial: 15648985
Drug: Diclofenac 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 15 mg
Trial: 11329407
Drug: 150 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/day of sustained‐release bupropion
Trial: 3307309
Drug: Insulin at
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin at 40 IU/ml (U40)
Trial: 3307309
Drug: Insulin at
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin at 100 IU/ml (U100)
Trial: 27054798
Drug: Vaginal hysterectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal hysterectomy with native tissue vault suspension
Trial: 27054798
Drug: Mesh hysteropexy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesh hysteropexy suspension
Trial: 26271057
Drug: Control of
RxNorm normalized name: A replication-competent adenovirus type 5 in which the E1A and E1B genes are under the control of a human telomerase reverse transcriptase (hTERT) and IRES, respectively.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control of 6 risk factors (no smoking, non-HDL cholesterol <130 mg/dl, triglycerides <150 mg/dl, blood pressure systolic <130 mm Hg; diastolic <80 mm Hg, glycosylated hemoglobin <7%)
Trial: 23675549
Drug: Coadministered treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministered treatment (ivermectin/albendazole/azithromycin)
Trial: 23675549
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (ivermectin/albendazole with azithromycin 1 week later)
Trial: 17661038
Drug: Glufosfamide 4,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glufosfamide 4,500 mg/m(2) + Gemcitabine 1,000 mg/m(2)
Trial: 12936918
Drug: Dietary fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary fish oil (0.3, 1, and 2 g eicosapentaenoic acid plus docosahexaenoic acid/d for 4 consecutive weeks)
Trial: 12936918
Drug: Antioxidant cosupplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant cosupplementation (200 microg Se, 3 mg Mn, 30 mg RRR‐alpha‐tocopheryl succinate, 90 mg ascorbic acid, 450 microg vitamin A)
Trial: 9106811
Drug: Intravenous sodium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sodium amytal (SA)
Trial: 3763944
Drug: BN 52063
RxNorm normalized name: MVA-BN
DrugBank: Modified vaccinia ankara (DB15483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BN 52063 (PAF antagonist) at a dose of 80 mg
Trial: 3763944
Drug: BN 52063
RxNorm normalized name: MVA-BN
DrugBank: Modified vaccinia ankara (DB15483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BN 52063 (PAF antagonist) at doses of 20, 40, 80, and 120 mg
Trial: 29735455
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL of 0.2% ropivacaine injection at acupoints Hegu and Sanyinjiao
Trial: 29735455
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline injection at acupoints Hegu and Sanyinjiao
Trial: 24164308
Drug: UVA1 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: UVA1 treatment (medium-dose, four times weekly for 3 months)
Trial: 21785863
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 50 mg/kg clofibrate and phototherapy
Trial: 15634716
Drug: NETE 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NETE 200 mg plus TU 1000 mg every 8 wk
Trial: 15634716
Drug: NETE 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NETE 200 mg plus TU 1000 mg every 12 wk
Trial: 15634716
Drug: TU 1000
RxNorm normalized name: PEMRYDI RTU 1000 MG in 100 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TU 1000 mg plus placebo every 12 wk
Trial: 4073878
Drug: Tetracycline hydrochloride
RxNorm normalized name: Tetracycline Hydrochloride
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline hydrochloride at 0.5 g every 6 h or doxycycline at 100 mg every 12 h for 30 days plus 1 g of streptomycin a day for 21 days (Group A)
Trial: 4073878
Drug: Rifampin at
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin at 15 mg/kg per day in a single morning dose plus 100 mg of doxycycline every 12 h for 30 days (Group B)
Trial: 31737351
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) delivered in 2 face-to-face sessions and 4 phone sessions
Trial: 29485323
Drug: Multi-ingredient dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-ingredient dietary preworkout supplement
Trial: 25283252
Drug: 3 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/day of oral collagen peptide (CP) for 4 weeks
Trial: 22484523
Drug: 300 mL
RxNorm normalized name: HYQVIA 30 GM / 300 ML Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mL of alcohol-free wine
Trial: 15949594
Drug: PVU group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVU group (2 courses of cisplatin 80 mg/m2, i.v. x 1 (day 1), vindesine 3 mg/m2, i.v. x 1 (days 1 and 8) and UFT 400 mg/day, p.o. for 2 years)
Trial: 15949594
Drug: UFT group
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT group (UFT 400 mg/day, p.o. for 2 years)
Trial: 10458542
Drug: Lentinan (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lentinan (2 mg) administered 7 days before surgery
Trial: 7791055
Drug: Topical ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ketorolac (Acular)
Trial: 7791055
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac (Voltaren)
Trial: 7791055
Drug: Control medication
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Dial Dandruff Control]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control medication (HypoTears)
Trial: 7791055
Drug: Oral acetaminophen
RxNorm normalized name: acetaminophen Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral acetaminophen #3
Trial: 2225696
Drug: Acetaminophen (2.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (2.7 gm/day)
Trial: 3144541
Drug: Amoxycillin 3
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin 3 g
Trial: 389351
Drug: Ampicillin 3
RxNorm normalized name: ampicillin 389 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin 3 g plus probenecid 1 g
Trial: 21255399
Drug: Social-skills training
RxNorm normalized name: Safety 1st Social Safety Pack KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social-skills training and parental training plus standard treatment
Trial: 20930708
Drug: Evening ingestion
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening ingestion of ACE inhibitors (benazepril, captopril, enalapril, lisinopril, perindopril, quinapril, ramipril, spirapril, trandolapril)
Trial: 20930708
Drug: Chronotherapy (timing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronotherapy (timing of treatment to body rhythms)
Trial: 16948837
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (hydrogel)
Trial: 9167508
Drug: Subanesthetic doses
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subanesthetic doses of ketamine
Trial: 7948468
Drug: Glucose ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose ingestion (100 mg)
Trial: 2893080
Drug: Captopril 25
RxNorm normalized name: captopril 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 25 mg thrice a day
Trial: 28279123
Drug: Oral clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clarithromycin (7.5 mg/kg, twice a day)
Trial: 18942898
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg bolus of pantoprazole followed by continuous infusion of 8 mg/h for 72 hours (group 0)
Trial: 18942898
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of pantoprazole administered intravenously daily (group 1)
Trial: 2445316
Drug: Flecainide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide (200 to 400 mg per day)
Trial: 2445316
Drug: Amiodarone (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (800 to 400 mg per day)
Trial: 24780069
Drug: G-G-A-A-C-C haplotype
RxNorm normalized name: penicillin G Prefilled Syringe [Bicillin L-A]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-G-A-A-C-C haplotype (carrying rs964184-G-allele)
Trial: 24780069
Drug: A-C-G-G-C-C haplotype
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A-C-G-G-C-C haplotype (carrying rs964184-C-allele)
Trial: 24780069
Drug: A-C-A-G-T-C haplotype
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A-C-A-G-T-C haplotype (carrying rs964184-C-allele)
Trial: 22375972
Drug: Nicotine patches
RxNorm normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patches (15 mg per 16 hours)
Trial: 23483627
Drug: istradefylline 20
RxNorm normalized name: istradefylline 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: istradefylline 20 mg/day
Trial: 18519872
Drug: istradefylline 60
RxNorm normalized name: istradefylline
DrugBank: Istradefylline (DB11757)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: istradefylline 60 mg/day
Trial: 2140748
Drug: Polyvalent oral
RxNorm normalized name: polyvalent Crotalidae antivenin
DrugBank: Viper antivenom (DB14114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyvalent oral bacterial vaccine
Trial: 343312
Drug: Panidazole (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panidazole (1.0 - 2.0 g per day for 6 days)
Trial: 343312
Drug: Metronidazole (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (1.0 - 2.0 g per day for 6 days)
Trial: 343312
Drug: Panidazole (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panidazole (1.0 g per day for 7 days)
Trial: 343312
Drug: Panidazole (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panidazole (1.0 g per day for 10 days)
Trial: 31968697
Drug: Dietary advice
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary advice including green vegetables five times per week, beef three times per week, 300 mL whole milk per day, and whole dairy butter on bread every day plus standard supportive care.
Trial: 22402673
Drug: Oral 150
RxNorm normalized name: carbidopa
DrugBank: Carbidopa (DB00190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral 150 mg monthly ibandronate
Trial: 11920413
Drug: Pamidronate 10
RxNorm normalized name: pamidronate 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate 10 mg
Trial: 11480815
Drug: 0.1% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% chlorhexidine (CHX) solution
Trial: 11480815
Drug: Amine fluoride/stannous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amine fluoride/stannous fluoride (ASF) solution
Trial: 8035399
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received treatment after 3 months.
Trial: 2538577
Drug: CEV regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEV regimen (cyclophosphamide 1,000 mg/m2 IV day 1, vincristine 1.4 mg/m2 IV day 1, etoposide 50 mg/m2 IV day 1, followed by etoposide 100 mg/m2/day orally days 2 through 5)
Trial: 2538577
Drug: CAV regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAV regimen (cyclophosphamide 1,000 mg/m2 IV day 1, vincristine 1.4 mg/m2 IV day 1, doxorubicin 50 mg/m2 IV day 1)
Trial: 2538577
Drug: CV regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CV regimen (cyclophosphamide 2,000 mg/m2 day 1, vincristine 1.4 mg/m2 IV day 1)
Trial: 983073
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg pentazocine plus 500 mg acetylsalicylic acid (P + A)
Trial: 11724948
Drug: Chlorophyllin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorophyllin (100 mg, three times a day for 4 months)
Trial: 7370145
Drug: Meptazinol 100
RxNorm normalized name: meptazinol 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meptazinol 100 mg
Trial: 8405626
Drug: Pethidine 75
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pethidine 75 mg
Trial: 27383377
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg spironolactone (MR antagonist)
Trial: 26310855
Drug: Topical anesthetic
RxNorm normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical anesthetic (EMLA® or Numby®) plus subcutaneous buffered lidocaine (SQBL)
Trial: 26310855
Drug: Topical anesthetic
RxNorm normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical anesthetic (EMLA® or Numby®) only
Trial: 26310855
Drug: Topical anesthetic
RxNorm normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical anesthetic (EMLA® or Numby®) plus SQBL
Trial: 23526241
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg and Aspirin 150 mg capsule (test formulation)